Hims & Hers Health (NYSE: HIMS)
Hims & Hers Health Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Hims & Hers Health Company Info
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
News & Analysis
Where Will Hims & Hers Be in 5 Years?
Could this be the telehealth breakout Wall Street is underestimating?
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
The stock remains very volatile.
Why Hims & Hers Stock Sank This Week
The telehealth platform is growing quickly but is in the middle of a legal battle.
Should You Buy Hims & Hers Stock on the Dip?
The healthcare company is experiencing excellent sales growth, but investors are concerned about its longer-term prospects.
Hims & Hers: A Game-Changer in Telehealth or Just Another Fad?
Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks involved in this insightful analysis.
These Are the Smartest Growth Stocks to Invest $1,000 in Today
These growth stocks come from completely different industries, but each has something to offer long-term investors.
Stock Market Today: Hims & Hers Tumbles 12% on Revenue Miss Despite 73% Growth
Hims & Hers stock fell sharply Tuesday after the company missed Q2 revenue estimates, despite strong growth and reaffirmed guidance.
Why Hims & Hers Health Stock Just Dropped
Hims & Hers stock just got cheaper -- and it's still too expensive to buy.
Valuation
Podcast Episodes
This Weight Loss Partnership Was a Short One
None
Digesting Super Bowl Ads, Dunkin' & Starbucks Plans, and Some Weight Loss Drug News
The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime.
A New Name in Weight Loss Drugs
Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.